Retinoblastoma: Intravitreal Chemotherapy

Chapter

Abstract

The poor prognostic value of diffuse vitreous seeding (primary) is a hallmark of advanced retinoblastoma characterizing group D eyes in the International Classification of Retinoblastoma [1]. The presence of vitreous seeds has long been recognized as a major risk factor for eye survival. Reese [2] already noted that the prognosis of eyes with vitreous seeding at presentation was “very unfavorable” and classified them in the worst eye group (Vb).

Keywords

Toxicity Dust Retina Coherence Syringe 

References

  1. 1.
    Murphree AL. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18:41–53.CrossRefGoogle Scholar
  2. 2.
    Reese AB. Tumors of the eye. 2nd ed. New York: Harper & Row; 1963.Google Scholar
  3. 3.
    Gombos DS, Cauchi PA, Hungerford JL, et al. Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor? Br J Ophthalmol. 2006;90(9):1168–72.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Parness-Yossifon R, Bryar PJ, Weinstein JL, et al. Sudden dispersion of retinoblastoma shortly after initial chemotherapy treatment. Am J Ophthalmol. 2009;147(5):903–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Ericson LA, Rosengren BH. Present therapeutic resources in retinoblastoma. Acta Ophthalmol (Copenh). 1961;39:569–76.CrossRefGoogle Scholar
  6. 6.
    Seregard S, Kock E, af Trampe E. Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol. 1995;79(2):194–5.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Kivela T, Eskelin S, Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology. 2011;118(8):1689.e1–6.CrossRefGoogle Scholar
  8. 8.
    Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987;78(8):858–68.PubMedGoogle Scholar
  10. 10.
    Ueda M, Tanabe J, Inomata M, et al. Study on conservative treatment of retinoblastoma–effect of intravitreal injection of melphalan on the rabbit retina. Nihon Ganka Gakkai Zasshi. 1995;99(11):1230–5.PubMedGoogle Scholar
  11. 11.
    Suzuki S, Kaneko A. Vitreous injection therapy of melphalan for retinoblastoma. In: XV Biannual Meeting ISOO 2011 International Society of Ocular Oncology Committee, Buenos Aires, 2011.Google Scholar
  12. 12.
    Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Smith SJ, Pulido JS, Salomao DR, et al. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. Br J Ophthalmol. 2012;96(8):1073–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Abramson DH, Beaverson KL, Chang ST, et al. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122(9):1316–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133(5):657–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96(4):499–502.PubMedCrossRefGoogle Scholar
  17. 17.
    Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118(10):2081–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Shields CL, Honavar SG, Shields JA, et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol. 2002;120(4):460–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Abouzeid H, Moeckli R, Gaillard MC, et al. (106)Ruthenium brachytherapy for retinoblastoma. Int J Radiat Oncol Biol Phys. 2008;71(3):821–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Abramson DH, Ellsworth RM, Rosenblatt M, et al. Retreatment of retinoblastoma with external beam irradiation. Arch Ophthalmol. 1982;100(8):1257–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Brodie SE, Munier FL, Francis JH, et al. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol. 2013;126(1):79–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Retinoblastoma ClinicJules-Gonin Eye HospitalLausanneSwitzerland
  2. 2.Laboratory of Ocular PathologyJules-Gonin Eye HospitalLausanneSwitzerland

Personalised recommendations